Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

doi:10.1200/JCO.19.00895

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2020

Dao Kim-Hien T, Gotlib Jason, Deininger Michael M N, Oh Stephen T, Cortes Jorge E, Collins Robert H, Winton Elliot F, Parker Dana R, Lee Hyunjung, Reister Anna, Schultz, Savage Samantha, Stevens, Brockett Chase, Subbiah Nan, Press Richard D, Raess Philipp W, Cascio Michael, Dunlap Jennifer, Chen Yiyi, Degnin Catherine, Maxson Julia E, Tognon Cristina E, Macey Tara, Druker Brian J, Tyner Jeffrey W

Abstract excerpt

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1/2 inhibitor ruxolitinib in patients with CNL and aCML, irrespective of CSF3R mutation status. METHODS: We conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Nitriles

Share to Protein Kinase Inhibitors

Share to Pyrazoles

Share to Pyrimidines

Share to Receptors, Colony-Stimulating Factor

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 31880950
DOI: 10.1200/JCO.19.00895
PMCID: PMC7106977

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.PMID 31880950Read ↗

Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.Semantic proximity Read ↗

Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia.Semantic proximity Read ↗

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.Semantic proximity Read ↗

Expanding the Spectrum of CSF3R Mutated Myeloid Neoplasm Beyond Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia: A Comprehensive Analysis of 13 CasesSemantic proximity Read ↗

Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.Semantic proximity Read ↗

Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice.Semantic proximity Read ↗

What's different about atypical CML and chronic neutrophilic leukemia?Semantic proximity Read ↗

Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.Semantic proximity Read ↗

Successful Allogeneic Stem Cell Transplantation with Ruxolitinib Maintenance Therapy for CSF3R T618I Mutant Chronic Neutrophilic LeukemiaSemantic proximity Read ↗

CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia.Semantic proximity Read ↗

Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.Semantic proximity Read ↗

Current strategies in the diagnosis and management of chronic neutrophilic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.